- Home
- ANAB vs CTLP Comparison
ANAB vs CTLP Comparison
Compare ANAB & CTLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CTLP
- Stock Information
- Founded
- ANAB 2005
- CTLP 1992
- Country
- ANAB United States
- CTLP United States
- Employees
- ANAB N/A
- CTLP N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CTLP EDP Services
- Sector
- ANAB Health Care
- CTLP Technology
- Exchange
- ANAB Nasdaq
- CTLP Nasdaq
- Market Cap
- ANAB 621.1M
- CTLP 642.2M
- IPO Year
- ANAB 2017
- CTLP N/A
- Fundamental
- Price
- ANAB $23.41
- CTLP $11.08
- Analyst Decision
- ANAB Buy
- CTLP Hold
- Analyst Count
- ANAB 10
- CTLP 5
- Target Price
- ANAB $44.25
- CTLP $11.50
- AVG Volume (30 Days)
- ANAB 566.9K
- CTLP 3.1M
- Earning Date
- ANAB 08-04-2025
- CTLP 05-08-2025
- Dividend Yield
- ANAB N/A
- CTLP N/A
- EPS Growth
- ANAB N/A
- CTLP 404.65
- EPS
- ANAB N/A
- CTLP 0.80
- Revenue
- ANAB $111,872,000.00
- CTLP $292,642,000.00
- Revenue This Year
- ANAB N/A
- CTLP $15.56
- Revenue Next Year
- ANAB $24.39
- CTLP $14.42
- P/E Ratio
- ANAB N/A
- CTLP $13.79
- Revenue Growth
- ANAB 387.20
- CTLP 12.51
- 52 Week Low
- ANAB $12.21
- CTLP $5.82
- 52 Week High
- ANAB $41.31
- CTLP $11.36
- Technical
- Relative Strength Index (RSI)
- ANAB 57.46
- CTLP 74.77
- Support Level
- ANAB $21.87
- CTLP $10.96
- Resistance Level
- ANAB $24.69
- CTLP $11.10
- Average True Range (ATR)
- ANAB 1.19
- CTLP 0.07
- MACD
- ANAB -0.09
- CTLP -0.03
- Stochastic Oscillator
- ANAB 61.20
- CTLP 96.96
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CTLP Cantaloupe Inc.
Cantaloupe Inc operates in the small ticket electronic payments industry. It provides wireless, cashless, micro-transactions, and networking services within the unattended Point of Sale (POS) market. Its products and services portfolio consists of ePort Cashless devices, eSuds, EnergyMisers, and Value-added services which include Loyalty and Prepaid, Intelligent Vending, and others. The company offers services to different industries covering car wash, taxi and transportation, laundry, vending, kiosk, amusement, and arcade. The company derives revenue from the sale or lease of equipment and services to the small ticket, unattended POS market, and the majority of its revenue is derived from subscription and transaction fees.